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Pre-treatment differences in serotonergic binding between those who remit to antidepres-
sant treatment and those who do not have been found using Positron EmissionTomography
(PET). To investigate these differences, an exploratory study was performed using a sec-
ond imaging modality, diffusion-weighted MRI (DW-MRI). Eighteen antidepressant-free
subjects with Major Depressive Disorder received a 25-direction DW-MRI scan prior to
8 weeks of selective serotonin reuptake inhibitor treatment. Probabilistic tractography was
performed between the midbrain/raphe and two target regions implicated in depression
pathophysiology (amygdala and hippocampus). Average fractional anisotropy (FA) within the
derived tracts was compared between SSRI remitters and non-remitters, and correlation
between pre-treatment FA values and SSRI treatment outcome was assessed. Results
indicate that average FA in DW-MRI-derived tracts to the right amygdala was significantly
lower in non-remitters (0.55±0.04) than remitters (0.61±0.04, p<0.01). In addition, there
was a significant correlation between average FA in tracts to the right amygdala and SSRI
treatment response. These relationships were found at a trend level when using the left
amygdala as a tractography target. No significant differences were observed when using
the hippocampus as target. These regional differences, consistent with previous PET find-
ings, suggest that the integrity and/or number of white matter fibers terminating in the
right amygdala may be compromised in SSRI non-remitters. Further, this study points to
the benefits of multimodal imaging and suggests that DW-MRI may provide a pre-treatment
signature of SSRI depression remission at 8 weeks.
Keywords: diffusion-weighted MRI, major depressive disorder, tractography, amygdala, hippocampus, treatment
prediction, selective serotonin reuptake inhibitors
INTRODUCTION
Treatment selection for Major Depressive Disorder (MDD) is a
process of trial and error since there are currently no clinical pre-
dictors of treatment efficacy on an individual level (Taylor et al.,
2005; Leuchter et al., 2010). To reduce the morbidity and mortality
associated with MDD, there is a critical need to identify such bio-
markers (Taylor et al., 2005; Leuchter et al., 2010). Due to the role
of the serotonergic system in the pathophysiology of depression
(Meltzer, 1990; Ressler and Nemeroff, 2000) and the fact that the
most common first-line antidepressants, selective serotonin reup-
take inhibitors (SSRIs), target the serotonin transporter (Leuchter
et al., 2008), an index of serotonergic health may provide this
prognostic indicator (Miller et al., 2008, 2012a; Tenke et al., 2010).
As a promising example of this, lower pre-treatment serotonin
transporter (5-HTT) binding in the amygdala, midbrain, and ante-
rior cingulate, as assessed using positron emission tomography
(PET), has been associated with non-remission of MDD after
1 year of open naturalistic treatment (Miller et al., 2008). Sim-
ilarly, lower pre-treatment 5-HT1A autoreceptor binding in the
raphe nucleus, the region from which most serotonergic neurons
originate (Cook et al., 2006; Liu et al., 2010), has been associ-
ated with non-remission of MDD after 8 weeks of SSRI treatment
(Miller et al., 2012a).
To better understand whether these indices can predict anti-
depressant response, it may be helpful to examine the neuro-
biological basis of the serotonergic binding differences between
those who remit to treatment (remitters) and those who do not
(non-remitters). In particular, the reportedly lower pre-treatment
5-HT1A and 5-HTT binding in non-remitters may be due to
either diminished health and/or number of serotonergic fibers
or reduced 5-HT1A expression. These possibilities may be exam-
ined using Diffusion-Weighted MRI Imaging (DW-MRI), which
measures the diffusion of water molecules to assess imaged tis-
sue properties (Beaulieu, 2002). Using DW-MRI, estimates of
the directionality of water diffusion, called fractional anisotropy
(FA), can be calculated at each voxel. FA values range from zero
(isotropic diffusion) to one (anisotropic diffusion; Ressler and
Nemeroff, 2000) and have been used as an index of the health of
the identified fiber (white matter) tracts, with higher FA potentially
reflecting a parallel organization of axons and greater myelination
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(Beaulieu, 2002; Sexton et al., 2009). In addition, DW-MRI can be
used to identify fiber trajectory and number between a seed and
target region.
Several studies have used DW-MRI to examine abnormalities
in white matter associated with mood disorders (Sexton et al.,
2009). A 2009 review of DW-MRI studies reported that a signifi-
cant reduction in FA was observed in the frontal lobes of depressed
subjects in six of the seven studies that examined that region (Sex-
ton et al., 2009). Three of those studies also found lower FA in
the temporal lobes (Sexton et al., 2009). A further meta-analysis
examination of voxel-wise FA studies found a consistent effect of
decreased white matter FA in the superior longitudinal fasciculus
that correlated with number, intensity, and treatment history of
depressive episodes (Murphy and Frodl, 2011). Similarly, it has
been shown that lower FA in the inferior frontal brain region cor-
relates with greater severity of depression symptoms in late-life
depression (Nobuhara et al., 2006).
Based on the above studies, it is clear that trends are beginning
to emerge regarding DW-MRI-measured changes in depressed
individuals. However, a clinically useful measure has yet to be
derived from this modality. On that front, combining PET-based
measures with DW-MRI identified fiber tracts can enhance the
information provided by both modalities. Due to the complex
nature of depression and, more specifically, antidepressant treat-
ment response, it is helpful to use such a multimodal approach to
probe observed neurobiological differences (Sexton et al., 2009).
Therefore, in this study, the basis of previous serotonergic PET
findings was examined by identifying the location and health
of DW-MRI-derived tracts between the raphe/midbrain and two
target regions: the amygdala and hippocampus.
The amygdala was chosen as a target since dysfunction in
amygdala circuitry has been reported in depression and anxi-
ety (LeDoux, 2003; Holmes, 2008; Lowry et al., 2008; Jasinska
et al., 2012). Additionally, as stated above, pre-treatment 5-HTT
amygdala binding differences were found in antidepressant remit-
ters compared with non-remitters (Miller et al., 2012a). The
hippocampus has also been implicated in depression and antide-
pressant action (Lopez et al., 1998; McEwen and Magarinos, 2001;
Jabeen Haleem, 2011) although we have not found pre-treatment
serotonergic binding differences (using PET) in this region.
The DW-MRI analysis was performed on a subset of MDD
subjects whose pre-treatment serotonergic expression was exam-
ined using PET (Miller et al., 2012a). These subjects were therefore
investigated, prior to SSRI treatment, with two modalities. Using
this multimodal approach may afford a richer understanding of
potential antidepressant treatment response biomarkers, which
would provide clinicians much needed guidance in choosing
effective treatment strategies.
MATERIALS AND METHODS
SUBJECT INCLUSION/EXCLUSION CRITERIA
Depressed subjects
This study was approved by the Institutional Review Board of the
New York State Psychiatric Institute. All subjects were included
after providing informed consent. Subjects with DSM-IV MDD
were recruited through online and print advertisements, as well
as through referrals from neighboring outpatient clinics as part
of an SSRI prediction treatment study using PET. In that study,
PET imaging was performed using two tracers, [11C]WAY-100635
(Mathis et al., 1994) and [11C]DASB (Houle et al., 2000), on the
same day prior to SSRI treatment (Miller et al., 2012a,b). Of the
24 subjects with MDD reported in that study, 18 also received
a 25-direction diffusion-weighted MR image prior to treatment
(within 1 week of the PET scans). These 18 subjects are described
in Table 1. As previously outlined (Miller et al., 2012a), study
eligibility was assessed by psychiatric and medical history, chart
review, physical examination, routine blood tests, pregnancy test,
and urine toxicology. Inclusion criteria consisted of: (1) age 18–65;
(2) ability to provide informed consent; (3) meeting the DSM-
IV criteria for MDD and in a current major depressive episode;
(4) 17-item Hamilton Depression Rating Scale (HAM-D) score
greater than or equal to 15; (5) general health and absence of
unstable medical conditions; and (6) for subjects currently tak-
ing antidepressants: lack of benefit after trial of adequate dose
and duration. Exclusion criteria included: (1) Alcohol or sub-
stance use disorder within 6 months of scan; (2) other current or
past major psychiatric disorders including bipolar disorder, schiz-
ophrenia, schizoaffective illness, or psychotic disorders (comorbid
anxiety disorders allowed), anorexia nervosa or bulimia nervosa
in the past year; (3) for subjects< 33 years old, a first-degree
family history of schizophrenia (to exclude individuals possibly
presenting with the prodrome of schizophrenia); (4) inability to
discontinue psychotropic drugs that may interfere with 5-HTT
or 5-HT1A receptors for at least 3 weeks (6 weeks for fluoxetine)
prior to scanning, or history of significant decompensation dur-
ing medication washout; (5) pregnancy, current lactation, or plans
to conceive during the course of study participation; (6) use of
any anti-coagulant/anti-platelet treatment with the exception of
aspirin within 10 days; (7) IV drug or ecstasy use within the past
5 years; (8) dementia; (9) prior history of head trauma; (10) lack of
response to >2 trials of antidepressant monotherapy of adequate
dose and duration; (11) active suicidal ideation warranting inpa-
tient admission or requiring immediate treatment intervention;
(12) metal implants; (13) current or past exposure to radiation; or
(14) lifetime history of glaucoma.
Table 1 | Subject clinical and demographic information.
Non-remitters
(n=10)
Remitters
(n=8)
p-value
Age 31.2±11.3 34.3±14.6 0.61
Baseline Hamilton (24-item) 24.4±4.4 25.5±7.1 0.69
Final Hamilton (24-item) 16.3±2.5 5.1±3.1 0.00
Duration of treatment (days) 65.1±13.7 65.8±5.4 0.90
Beck depression inventory 26.9±8.5 23.8±11.6 0.52
Beck hopelessness inventory 9.6±5.0 7.6±9.9 0.63
Lifetime aggression 16.0±4.0 13.3±2.5 0.38
Age of first depressive episode 23.6±10.8 17.6±2.5 0.15
# Females (%) 7 (70%) 4 (50%) 0.63*
# Suicide attempters (%) 4 (40%) 1 (13%) 0.31*
*p-value calculated by Fisher’s exact test.
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STUDY PROTOCOL
To reduce any confounds associated with multiple drug targets,
a study drug highly selective for the serotonin transporter was
needed. Escitalopram was therefore chosen because it is the most
selective SSRI available (Owens and Rosenbaum, 2002). Addition-
ally, escitalopram has been shown to have equal or greater effec-
tiveness than other available SSRIs as well as favorable tolerability
(Kirino, 2012).
All subjects were antidepressant-free for at least 23 days prior
to imaging. Following baseline imaging, treatment was initiated
with escitalopram at a dose of 10 mg daily for the first 4 weeks. At
4 weeks, escitalopram non-responders (those with <50% reduc-
tion in 24-item HDRS) had escitalopram increased to 20 mg.
At 6 weeks, escitalopram non-remitters who were still taking
10 mg had escitalopram increased to 20 mg. Remission, assessed at
approximately 8 weeks, was defined as a final 24-item HDRS< 10
and ≥50% reduction in HDRS from baseline.
IMAGING TECHNIQUES
Anatomical
Anatomical magnetic resonance images (MRIs) were acquired on
a 3.0T Signa Advantage system (GE Healthcare, Waukesha, WI,
USA), as previously described (Ogden et al., 2007).
Each subject’s MRI was processed using the freely available
Freesurfer software1. This parcellation (using the Desikan Kil-
liany atlas) provided anatomical delineation of multiple regions
including the midbrain, left and right amygdala, and left and right
hippocampus.
Diffusion imaging
Diffusion-weighted MRI scans were acquired using a single-shot
echo planar imaging (EPI) sequence. Scan parameters were as
follows: TR (repetition time): 14000 ms, TE (echo time): 83 ms,
Flip Angle: 90˚, slice thickness: 3 mm, FOV (field of view):
240 mm× 240 mm, voxel dimensions: 0.94 mm× 0.94 mm×
3 mm, acquisition matrix: 132× 128, b-value: 1000 s/mm2, and
25 collinear directions with five non-weighted images.
Each DW-MRI image was run through a series of quality assur-
ance tests for artifacts common to DW-MRI, including ghost
and/or ring artifact, slice wise intensity-related artifact, venetian
blind effect, and gradient-wise motion artifact (Liu et al., 2010).
After passing this inspection, the diffusion image was corrected for
distortion induced by the gradient coils and simple head motion
using the eddy correction routine within FSL (FMRIB Software
Library2). Following this, Camino (Cook et al., 2006) was used to
fit the diffusion tensor, using a positive constraint, and estimate
FA at each voxel.
PET-derived raphe atlas
In a separate study (unrelated to SSRI treatment), 52 healthy con-
trols were previously scanned using PET and the tracer [11C]WAY-
100635, which targets the 5-HT1A receptor (Parsey et al., 2010).
Voxel binding maps were calculated, warped to a standard image
space, and averaged (Parsey et al., 2010). (Each subject’s MRI
1http://surfer.nmr.mgh.harvard.edu/
2http://www.fmrib.ox.ac.uk/fsl/
was first non-linearly warped using the symmetric normalization
routine in the Advanced Normalization Tools, ANTs (Avants et al.,
2008), to a high-resolution template (Holmes et al., 1998). The
resulting non-linear transform was then used to bring each sub-
ject’s voxel map into the template space). Since 5-HT1A binding is
higher in the raphe nuclei than surrounding regions, a threshold-
ing technique was used to extract the nuclei from the average voxel
image. This extracted raphe could be applied to any subject’s MRI
by warping the subject’s MRI to the template space, and applying
the inverse warp to the raphe template.
Seed region
Each anatomical MRI was non-linearly warped to the subject’s cor-
responding field map-corrected DW-MRI image using ANTs. With
the calculated transformation, Freesurfer ROIs and the template-
based raphe nuclei (both in anatomical MRI space) could be
non-linearly warped to DW-MRI space. The freesurfer-delineated
midbrain ROI was then merged with the raphe nuclei extracted
from the PET template to ensure that the combined region fully
encompassed the raphe, and this combined region was used as a
seed for the tractography. The midbrain was used in conjunction
with the raphe because the resolution of 25-direction DW-MRI
prevented accurate quantification of tracts from the raphe alone.
Tractography and weighted FA
Probabilistic tractography was performed using FMRIB’s Dif-
fusion Toolbox (FDT)3. This algorithm computes probabilistic
streamlines through each voxel by repetitive sampling from the
principal diffusion directions. The result of this procedure is the
probability of connections from the seed (midbrain plus raphe,
defined above) to either the amygdala or the hippocampus. The
algorithm was run with a tract curvature threshold of 0.2 mm,
maximum number of steps per sample equal to 2000, length of
each step equal to 0.5 mm, and 5000 samples. (Note that the result-
ing tract number is dependent on these initialization parameters,
and therefore may only be useful for relative comparisons.) In
order to calculate the (weighted) average FA within the defined
tracts, the voxel-based FA measures were multiplied by the prob-
ability of connection at each voxel and divided by the sum of the
probabilities.
RESULTS
TRACTOGRAPHY
Tractography results for one subject (right amygdala target) are
shown in Figure 1. As indicated in this Figure, tracts can be visu-
alized to ensure that they meaningfully connect seed and target
regions. In this figure, only voxel connections containing greater
than 40 tracts per voxel are shown.
CONNECTIVITY TO AMYGDALA
Average FA in fiber tracts (weighted by the connection probability)
to the right amygdala target (FAright_amy) was significantly lower in
non-remitters (0.55± 0.04) than remitters (0.61± 0.04, p< 0.01;
see Figure 2). At a trend level, the average FA in tracts to the
3http://www.fmrib.ox.ac.uk/fsl/fdt/fdt_probtrackx.html
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FIGURE 1 | Example of tractography results in one subject.The
magnetic resonance image (MRI) of one subject is shown. (Cutaway views
of a sagittal and axial slice). Overlaid on the MRI are volume renderings of
the midbrain (blue) containing the raphe nuclei (red), the right amygdala
(yellow), and the tracts between these regions (green). At each voxel, the
number of tracts between midbrain and right amygdala were determined
and used as weighting factors in the calculation of average fractional
anisotropy. Only voxels containing more than 40 tracts are shown.
left amygdala target (FAleft_amy) was also lower in non-remitters
(0.52± 0.05) versus remitters (0.56± 0.04, p= 0.06).
The total number of tracts generated between seed and target
varied substantially by subject. Therefore, to stabilize variances
and correct for any skew in the data, the log transform of the
total number of tracts to each target was computed. Using the log-
transformed values, on average, non-remitters had fewer tracts
to the right (3.18± 0.81) and left (3.12± 0.58) amygdala com-
pared to remitters (3.91± 0.74, p= 0.06 and 3.96± 0.63, p= 0.01,
respectively).
CONNECTIVITY TO HIPPOCAMPUS
In contrast to the amygdala findings, no significant differences
between the response groups were found in average FA values to
the right (FAright_hip) or left hippocampus target (FAleft_hip, see
Figure 2) or in number of tracts to these targets.
CONTINUOUS MEASURE OF TREATMENT OUTCOME
In addition to being classified as remitter or non-remitter, a sub-
ject’s percent change in depression score, defined as 100× (HAM-
Dbaseline−HAM-Dpost-treatment)/HAM-Dbaseline, could also be cal-
culated. Percent change in HAM-D was considered rather than
absolute change to account for the effect of the subject’s baseline
value on their potential change in HAM-D score. Using regres-
sion analysis, FAright_amy predicted percent change in depression
scores (b= 417.0, t = 3.68, df= 17, R2= 0.46, p= 0.002, Figure 3).
Using the same analysis, FAleft_amy had less predictive power
(b= 286.6, t = 2.05, df= 17, R2= 0.21, p= 0.06). Adding age and
total brain volume to the model did not improve the predictive
power of either FAright_amy (b= 193.6, t = 1.15, df= 17, R2= 0.08,
p= 0.27) or FAleft_amy (b= 108.1, t = 0.38, df= 17, R2= 0.01,
p= 0.71).
Since there is one subject whose depression worsened after
treatment (Figure 3), the regression analysis was repeated with
this subject removed. Without this subject, the FAright_amy finding
remained (b= 314.7, t = 2.89, df= 16, R2= 0.36, p= 0.01); how-
ever the FAleft_amy finding was diminished (b= 134.4, t = 0.96,
df= 16, R2= 0.06, p= 0.35).
CORRELATION TO 5-HT BINDING MEASURES AS ASSESSED BY PET
Since this study was motivated by PET results, a preliminary analy-
sis of the relationship between amygdala 5-HT1A binding and FA
was performed. For this analysis, 5-HT1A binding was quanti-
fied using the PET tracer[11C]WAY-100635 (Mathis et al., 1994)
and the outcome measure BPF, equivalent to Bavail/K D, where
Bavail is the density of available receptors and K D is the equi-
librium dissociation constant (Parsey et al., 2000; Innis et al.,
2007). Since [11C]WAY-100635 binding may be affected by sex,
medication status, and genotype (functional C-1019G promoter
polymorphism of the 5-HT1A gene; Lemonde et al., 2003), these
variables were used as covariates in the regression of raphe BPF
versus average FA (Miller et al., 2009). Of the 18 MDD sub-
jects, the frequency of each genotype was: CG: 10 (55.6%); CC:
4 (22.2%); GG: 3 (16.7%); and unknown in one subject (5.6%).
In addition, observations were weighted using estimates of BPF
measurement precision based on errors estimated by a bootstrap-
ping algorithm (Ogden and Tarpey, 2006; Miller et al., 2012a). No
significant correlation was found between left or right amygdala
5-HT1A binding and average FAleft_amy or FAright_amy (b=−1.14,
t =−0.02, df= 17, R2= 0.25, p= 0.99 and b=−23.81, t =−0.36,
df= 17, R2= 0.29, p= 0.73, for left and right respectively). Sim-
ilarly, no significant correlation was found between left or right
amygdala 5-HT1A binding and the log of the total number of tracts
to the left or right amygdala (b= 5.12, t = 1.18, df= 17, R2= 0.26,
p= 0.26 and b= 2.77, t = 0.63, df= 17, R2= 0.31, p= 0.54, for left
and right respectively).
Due to pre-treatment 5-HTT binding differences in the amyg-
dala of remitters versus non-remitters observed in a previous
cohort (Miller et al., 2008), the relationship of amygdala 5-HTT
binding to average FA was also evaluated. Serotonin transporter
binding was assessed using the PET tracer [11C]DASB (Houle et al.,
2000) and the outcome measure V T/fp, where V T is the volume
of distribution (or ratio of the concentration of the ligand in the
region to that in the plasma at equilibrium) and fp is the free frac-
tion (Innis et al., 2007; Mukhin et al., 2008; Ichise, 2009; Esterlis
et al., 2010; Chin et al., 2011; Fujita et al., 2012). For this analy-
sis, only 17 subjects could be used, because one subject did not
have [11C]DASB scan data available. As above, observations were
weighted using estimates of VT/fp measurement precision, based
on errors estimated by a bootstrapping algorithm (although no
covariates were used in this case; Ogden and Tarpey, 2006; Miller
et al., 2012a). No correlation was found between V T/fp in the
left or right amygdala and FAleft_amy or FAright_amy (b=−289.47,
t =−1.02, df= 16, R2= 0.06, p= 0.33 and b= 329.79, t = 1.16,
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FIGURE 2 | Mean fractional anisotropy values in the amygdala and hippocampus. DW-MRI images of were acquired of 18 depressed subjects prior to
SSRI treatment. The mean and standard deviation of those who remitted to treatment (n=8) and those who did not (n=10) is plotted.*p= 0.06, **p=0.007.
FIGURE 3 | Percent change in Hamilton depression scale score
(HAM-D) as a function of pre-treatment average fractional anisotropy.
Average fractional anisotropy (FA) was calculated using a weighted mean
of FA within the tracts from the midbrain/raphe to the left (FAleft_amy) or right
(FAright_amy) amygdala. The linear regression fits (black lines) and parameters
are indicated.
df= 16, R2= 0.08, p= 0.27, for left and right respectively). Simi-
larly, no correlation was found between V T/fp and the log of the
total number of tracts (b=−12.24, t =−0.58, df= 16, R2= 0.02,
p= 0.57 and b= 4.86, t = 0.29, df= 16, R2= 0.01, p= 0.78, for left
and right respectively).
DISCUSSION
This pilot study evaluated DW-MRI-derived tracts between the
midbrain/raphe and the amygdala or hippocampus. In previous
PET studies performed by our group, 5-HT1A raphe and 5-HTT
amygdala binding has been associated with antidepressant treat-
ment outcome in MDD. This study was an initial attempt to further
probe these observed differences, and to determine whether DW-
MRI-derived measures can be used as a potential predictor of SSRI
antidepressant response in MDD.
Previous PET findings indicated lower pre-treatment 5-HTT
binding in the amygdala (as well as lower 5-HT1A binding in the
raphe, the region from which most serotonergic neurons originate;
Miller et al., 2012a) in non-remitters compared with remitters
(Miller et al., 2008). Consistent with these findings, in this study,
significantly lower FAright_amy (in tracts originating from the mid-
brain/raphe) was observed in non-remitters. In addition to lower
average FA, the number of tracts to the right amygdala was lower
(at a trend level) in non-remitters versus remitters. Although both
FAleft_amy and number of tracts to the left amygdala were also
lower in non-remitters, the effect was stronger on the right side.
Similar findings were reported by a recent study using compara-
ble methodology (examination of FA within white matter tracts
from the subgenual anterior cingulate to the amygdala or supra-
genual cingulate). In that study, a significant difference in FA was
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observed between depressed adolescents and controls in the tracts
from the right subgenual anterior cingulate to the right amygdala
only (Cullen et al., 2010). Further investigation of possible lateral-
ity in FA differences in depression and as a function of treatment
outcome is therefore warranted. (It should be noted that, in the
PET study, left and right amygdala were combined (Miller et al.,
2008)). Interestingly, the Cullen et al. study found FA differences
using a different tractography seed (subgenual anterior cingulate).
This may suggest that the FA differences observed in the current
study are a consequence (and not a cause) of primary pathology
in the amygdala. Since causation cannot be determined from this
pilot study, this remains an open question.
The hippocampus is another region that has been implicated
in depression pathophysiology; however, we have not previously
found a significant correlation between serotonin receptor or
transporter binding in the hippocampus and antidepressant treat-
ment outcome. Correspondingly, no significant differences in FA
or number of tracts to the left or right hippocampus between non-
remitters and remitters were observed. This lends further credence
to the potential interrelation between serotonin findings and white
matter connectivity, as assessed by DW-MRI. However, due to
the small sample size and limitations listed below, a relationship
between FA in tracts to the hippocampus and remission status
cannot be ruled out without further studies in a larger cohort.
Since most serotonin fibers originate from the raphe, one
potential explanation based on the DW-MRI findings in combina-
tion with those from PET, is that subjects who remit to antidepres-
sant treatment have greater health and/or number of serotonergic
neurons originating in the raphe and terminating in the amygdala.
In this case, one might expect to see a correlation between FA (or
the number of tracts) and 5-HT or 5-HT1A binding; however, these
correlations were not statistically significant in this work. This may
have been due to the small sample size and/or the need for multi-
ple PET covariates (or other limitations discussed in 4.1). Lending
credence to this hypothesis, the statistically significant difference in
PET binding measures between remitters and non-remitters is not
replicated in sample of subjects who received DW-MRI imaging
(data not shown). (Although it should be noted, that in addi-
tion to the reduced sample size, the left and right amygdala were
also considered separately in this work, adding to variability in
the binding measurement). In addition, it is possible that a cor-
relation was not observed due to the heterogeneity of depression
itself. Since the etiology of depression is not known completely,
depression pathophysiology, as well as potential downstream anti-
depressant effects are not fully elucidated. The monoaminergic
system, glutamate, neurotrophic factors, and circadian rhythms
have all been implicated in MDD (Hasler, 2010). Therefore the
relationship between PET-based serotoninergic binding measures,
FA, and clinical outcomes may be much more complex than can
be explained through a simple correlation analysis. Future studies
will be needed to address these issues.
To further investigate the sensitivity of DW-MRI-derived mea-
sures to an individual’s SSRI treatment response, linear regression
analysis was performed. This analysis (Figure 3) indicates that
pre-treatment FAright_amy predicts some of the variance in the
degree of clinical improvement following SSRI treatment. One
potential interpretation is that the reduced regional white matter
connectivity (observed in non-remitters) can impair effective-
ness of antidepressant treatments, resulting in reduced depression
improvement. Further DW-MRI studies are needed to validate this
hypothesis. Examining the tracts to the left amygdala reveals that
FAleft_amy provides less predictive power of final depression scores,
especially when the single subject whose depression worsens is
removed. Similar to the FA results, this also suggests a stronger
effect on the right side.
This was a pilot study, and potentially the first to use DW-MRI
to predict antidepressant treatment response. As such, there were a
limited number of subjects examined (n= 18), and these subjects
were further divided into remitters and non-remitters based on
treatment response. Because of this, to avoid the loss of statisti-
cal power related to multiple comparisons, the scope of this work
was restricted to the evaluation of connectivity between the mid-
brain/raphe (from which most serotonergic fibers originate) and
two brain regions – the amygdala and hippocampus. The main
finding of this work is therefore related to the examination of the
average FA between these two groups. Although further analysis
(i.e., prediction of final Hamilton Depression Score or relation to
serotonin binding) was performed to aid in the interpretation of
the main finding, further detailed analysis was challenging due to
the following limitations.
LIMITATIONS
(1) Interpretation of DW-MRI results. Recent publications have
highlighted several issues related to DW-MRI interpretation
(Jones, 2010; Jones et al., 2012). There is remaining uncertainty
over the optimal method to reconstruct tracts from diffusion-
weighted images, and choice of software and underlying model
assumptions may greatly affect results (Fillard et al., 2011).
Although the probabilistic method used in this work has been
partially validated (Behrens et al., 2003) and is designed to handle
multiple fiber orientations (Behrens et al., 2007), novel applica-
tions of this technique (such as fiber tracking between the raphe
and amygdala) require further validation. (2) Anatomical valida-
tion. To fully interpret DW-MRI results, it is essential to validate
DW-MRI-derived results anatomically, which was not performed
as part of this pilot study (Jones, 2010). Since a“tract”is not derived
from a single neuron, it may represent a fiber bundle, or multiple
fiber bundles (Catani et al., 2002). It is therefore necessary to val-
idate that tractography results represent the serotonergic pathway
and not, for example, the more prevalent dopaminergic pathway
or a combination of fibers. (Although, when searching for a clini-
cally relevant biomarker of antidepressant treatment effectiveness,
it is only necessary to distinguish between groups). (3) The res-
olution of 25-direction DW-MRI. The resolution of DW-MRI is
determined, in large part, by the number of gradient directions
measured. The limited resolution of 25-direction DW-MRI may
have led to variability in the tractography results and prevented
using the small raphe region as a seed. Because of this, the mid-
brain (including the raphe) was used. However, this is unlikely to
have a great effect since, fibers from the midbrain that terminate
at the amygdala or hippocampus will most likely originate in the
raphe.
Despite the concerns listed above, the significant differences
observed in FAright_amy between treatment groups indicate that
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it is a robust finding and, as such, that DW-MRI-derived
measures may provide a pre-treatment indicator of antidepressant
response.
CONCLUSION
Selection of antidepressant treatment is a challenge for both
clinicians and patients. This pilot study was performed to deter-
mine the potential of DW-MRI-derived measures to provide a
pre-treatment indicator of SSRI response. A significant differ-
ence was observed in FAright_amy (average FA within white mat-
ter tracts between the raphe and the right amygdala) between
SSRI remitters and non-remitters. Moreover, there was a signif-
icant correlation between FAright_amy and percent improvement in
depression, as assessed by the Hamilton Depression Rating Scale
(HAM-D). These results suggest that the health and/or number of
serotonergic fibers terminating at the right amygdala may be com-
promised in SSRI non-remitters. Moreover, since these differences
were less robust in tracts terminating at the left amygdala and not
observed in tracts terminating at the hippocampus, the observed
effect may be localized regionally. However, due to limitations
in DW-MRI resolution and sample size, future work in a larger
cohort is required to confirm these findings. These initial find-
ings do suggest, however, that DW-MRI-based measures should
be further investigated as a potential pre-treatment signature of
antidepressant response.
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